Non-invasive cancer detection
July 14, 2022
Image credit: Singapore Business Review
In 2010, Dr ZHOU Lihan (Life Sciences, 2007) and his colleagues developed a way of detecting, with unparalleled sensitivity, the smallest strands of genetic material, known as microribonucleic acid (microRNA). MicroRNA is crucial in cell functions and aberrations could provide early indications of disease.
This discovery led to the birth of MiRXES, a multiple award-winning biotechnology company, which brings accurate and affordable RNA-based multi-cancer early diagnostic solutions to the world.
Video credit: Asian Scientist
During the pandemic, MiRXES also contributed its research and manufacturing capabilities to produce the Fortitude Kit 2.0, Singapore’s first approved COVID-19 test. Recently, MiRXES began a large-scale clinical study for a blood test that can offer early screening of up to nine different cancers that have high mortality rates.
Today, MiRXES’ platform is widely used to develop solutions for various diseases.
Dr Zhou said, “We started MiRXES to translate our benchtop research into solutions that impact people and save lives. We are proud to lead transformative healthcare efforts, from treating the sick to preventing illnesses.”
Find out more here.
